# Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma

> **NCT04838652** · PHASE2 · RECRUITING · sponsor: **University of Cologne** · enrollment: 29 (estimated)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Pembrolizumab plus Chemotherapy (ICE or DHAP)

## Key facts

- **NCT ID:** NCT04838652
- **Lead sponsor:** University of Cologne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-05
- **Primary completion:** 2026-05
- **Final completion:** 2028-05
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04838652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04838652, "Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04838652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*